News Breaks |
|
|
| August 10, 2012 |
| 08:47 EDT |  | MDVN | Medivation price target raised to $122 from $90 at Leerink
Leerink raised its price target for Medivation following the company's Q2 results citing increased probability of success for enzalutamide in post-chemo castration resistant prostate cancer. The firm keeps an Outperform rating on the stock. |
|
|
News For MDVN From The Last 14 Days Check below for free stories on MDVN the last two weeks. |
|
|
| May 14, 2013 |
| 14:59 EDT |  | MDVN | Medivation has a conference call hosted by JPMorgan
JPMorgan Analysts Meacham and Kasimov host a conference call with CEO David Hung on May 16 at 10 am. |
|
|
|
|
|
